David William Hedding, University of South AfricaA media storm blew up in mid-March 2025 when a researcher at South Africa’s isolated Sanae IV base in Antarctica accused one of its nine team members of becoming violent.
The Conversation Africa asked geomorphologist David William Hedding, who has previously carried out research from the frozen continent, about the work researchers do in Antarctica, what conditions are like and why it matters.
What do researchers focus on when they’re working in Antarctica?
Currently, the main focus of research in the Antarctic revolves around climate change because the White Continent is a good barometer for changes in global cycles. It has a unique and fragile environment. It’s an extreme climate which makes it highly sensitive to any changes in global climate and atmospheric conditions. Importantly, the Antarctic remains relatively untouched by humans, so we are able to study processes and responses of natural systems.
Also, the geographic location of Antarctic enables science that is less suitable elsewhere on the planet. An example of this is the work on space weather (primarily disturbances to the Earth’s magnetic field caused by solar activity). Studying space weather is significant because the magnetic field of the Earth can impact communication platforms, technology, infrastructure and...
Scientists in Antarctica: why they’re there and what they’ve found
Bug drugs: bacteria-based cancer therapies are finally overcoming barriers

Lightspring/Shutterstock
Justin Stebbing, Anglia Ruskin UniversityImagine a world where bacteria, typically feared for causing disease, are turned into powerful weapons against cancer. That’s exactly what some scientists are working on. And they are beginning to unravel the mechanisms for doing so, using genetically engineered bacteria to target and destroy cancer cells.
Using bacteria to fight cancer dates back to the 1860s when William B. Coley, often called the father of immunotherapy, injected bacteria called streptococci into a young patient with inoperable bone cancer. Surprisingly, this unconventional approach led to the tumour shrinking, marking one of the first examples of immunotherapy.
William Coley (centre), a pioneer of bug drugs. Wikimedia CommonsOver the next few decades, as head of the Bone Tumour Service at Memorial Hospital in New York, Coley injected over 1,000 cancer patients with bacteria or bacterial products. These products became known as Coley’s toxins.
Despite this early promise, progress in bacteria-based cancer therapies has been slow. The development of radiation therapy and chemotherapy overshadowed Coley’s work, and his approach faced scepticism from the medical community.
However, modern immunology has vindicated many of Coley’s principles, showing that some cancers are indeed very sensitive...
Subscribe to:
Posts (Atom)